Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRD001 Ultrasound Contrast Imaging for Ovarian Masses
NCT06556342Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Lipid-based Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Open-label, single-arm trial of FRD001 in ovarian cancer, sponsored by Tongji Hospital. Primary endpoint: Sensitivity at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
FRD001
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06556342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556342.